RBC Capital Reiterates Outperform on IGM Biosciences, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on IGM Biosciences (NASDAQ:IGMS) and maintained a $20 price target.
August 15, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on IGM Biosciences and maintained a $20 price target.
The reiteration of an Outperform rating and the maintenance of a $20 price target by a reputable analyst can boost investor confidence in IGM Biosciences, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100